RMD logo

ResMed Inc. (RMD)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

ResMed Inc. (RMD) trades at $228.22 with AI Score 52/100 (Hold). ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for respiratory disorders, notably sleep apnea. Market cap: $33.31B, Sector: Healthcare.

Last analyzed: Feb 9, 2026
ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for respiratory disorders, notably sleep apnea. The company operates through two segments, Sleep and Respiratory Care, and Software as a Service, serving patients in approximately 140 countries.
52/100 AI Score Target $287.40 (+25.9%) MCap $33.31B Vol 242.9K

ResMed Inc. (RMD) Healthcare & Pipeline Overview

CEOMichael J. Farrell
Employees9980
HeadquartersSan Diego, CA, US
IPO Year1995

ResMed Inc. pioneers innovative medical devices and cloud-based solutions for respiratory care, offering a notable research candidate driven by a strong market position, recurring revenue model, and increasing adoption of digital health technologies, targeting a growing global patient base and delivering a robust 27.5% profit margin.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 9, 2026

Investment Thesis

ResMed presents a notable research candidate driven by the increasing prevalence of sleep apnea and other respiratory disorders, coupled with the growing adoption of digital health solutions. The company's established market leadership, recurring revenue model from devices and SaaS offerings, and strong profitability (27.5% profit margin) underpin its investment appeal. Key growth catalysts include expanding its cloud-based software solutions, penetrating emerging markets, and capitalizing on technological advancements in respiratory care. ResMed's commitment to innovation, coupled with its robust distribution network, positions it to sustain long-term growth and deliver shareholder value. The company's dividend yield of 0.83% offers a supplementary return, further enhancing its investment attractiveness.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $39.65 billion reflects ResMed's significant presence in the medical devices market.
  • P/E ratio of 26.78 indicates investor confidence in ResMed's earnings potential.
  • Gross margin of 61.0% demonstrates efficient cost management and strong pricing power.
  • Profit margin of 27.5% highlights ResMed's ability to generate substantial profits from its operations.
  • Dividend yield of 0.83% provides a steady income stream for investors.

Competitors & Peers

Strengths

  • Market leader in sleep apnea devices and solutions.
  • Strong brand reputation and customer loyalty.
  • Recurring revenue model from devices and software subscriptions.
  • Extensive distribution network and global presence.

Weaknesses

  • Reliance on reimbursement policies and healthcare regulations.
  • Competition from established and emerging players.
  • Potential for product recalls or safety concerns.
  • Exposure to currency fluctuations and international risks.

Catalysts

  • Ongoing: Increasing prevalence of sleep apnea and other respiratory disorders.
  • Ongoing: Growing adoption of digital health solutions and remote patient monitoring.
  • Upcoming: Launch of new respiratory care devices and software solutions in 2026.
  • Ongoing: Expansion into emerging markets with strategic partnerships.
  • Upcoming: Positive clinical trial results for new therapies or devices in Q3 2026.

Risks

  • Potential: Changes in reimbursement policies or healthcare regulations could impact revenue.
  • Potential: Technological advancements by competitors could erode market share.
  • Ongoing: Economic downturns or healthcare spending cuts could reduce demand.
  • Potential: Product liability claims or intellectual property disputes could damage reputation.
  • Ongoing: Currency fluctuations and international risks could impact profitability.

Growth Opportunities

  • Expanding Cloud-Based Software Solutions: ResMed has the opportunity to further expand its cloud-based software solutions, such as AirView and myAir, to enhance patient engagement and improve therapy adherence. The market for remote patient monitoring is projected to reach $30 billion by 2028, offering significant growth potential for ResMed's SaaS segment. By leveraging its existing customer base and developing new features, ResMed can capture a larger share of this market.
  • Penetrating Emerging Markets: ResMed can capitalize on the growing demand for respiratory care solutions in emerging markets, such as China and India. These markets have a large and underserved patient population, presenting a significant growth opportunity for ResMed's devices and software solutions. By establishing strategic partnerships and tailoring its products to local needs, ResMed can gain a competitive advantage in these markets.
  • Developing Innovative Respiratory Care Devices: ResMed can continue to invest in research and development to create innovative respiratory care devices that address unmet patient needs. The company's expertise in ventilation and sleep apnea therapy positions it to develop next-generation devices that offer improved efficacy, comfort, and ease of use. These innovations can drive revenue growth and strengthen ResMed's market leadership.
  • Acquiring Complementary Businesses: ResMed can pursue strategic acquisitions to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or market access, ResMed can accelerate its growth and diversify its revenue streams. Potential acquisition targets include companies in the areas of respiratory diagnostics, home healthcare services, and digital health solutions.
  • Increasing Awareness and Diagnosis of Sleep Apnea: ResMed can partner with healthcare providers and advocacy groups to increase awareness and diagnosis of sleep apnea. Many individuals with sleep apnea remain undiagnosed, representing a significant untapped market for ResMed's products. By educating patients and healthcare professionals about the symptoms and risks of sleep apnea, ResMed can drive increased diagnosis rates and expand its customer base.

Opportunities

  • Expanding into emerging markets with underserved patient populations.
  • Developing innovative respiratory care devices and software solutions.
  • Acquiring complementary businesses to expand product portfolio.
  • Increasing awareness and diagnosis of sleep apnea.

Threats

  • Changes in reimbursement policies or healthcare regulations.
  • Technological advancements by competitors.
  • Economic downturns or healthcare spending cuts.
  • Product liability claims or intellectual property disputes.

Competitive Advantages

  • Strong brand reputation and established market leadership in the respiratory care market.
  • Extensive patent portfolio protecting its innovative technologies.
  • Recurring revenue model from devices, accessories, and software subscriptions.
  • Robust distribution network and established relationships with healthcare providers.
  • Switching costs for patients using ResMed's devices and software solutions.

About RMD

Founded in 1989 and headquartered in San Diego, California, ResMed Inc. has evolved into a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the healthcare market. The company's core focus lies in addressing respiratory disorders, particularly sleep apnea, through its Sleep and Respiratory Care segment. ResMed offers a comprehensive suite of products, including continuous positive airway pressure (CPAP) devices, ventilation devices, diagnostic products, and mask systems for both hospital and home use. Complementing its hardware offerings, ResMed's Software as a Service (SaaS) segment provides cloud-based informatics solutions that enable remote patient monitoring, therapy management, and improved patient engagement. Key SaaS products include AirView, myAir, and U-Sleep. ResMed also provides out-of-hospital software solutions such as Brightree, MatrixCare, and HEALTHCAREfirst, catering to various healthcare providers. With a presence in approximately 140 countries, ResMed markets its products through a network of distributors and a direct sales force, serving sleep clinics, home healthcare dealers, and hospitals. The company's commitment to innovation and patient-centric solutions has solidified its position as a key player in the respiratory care market.

What They Do

  • Develops and manufactures medical devices for respiratory disorders.
  • Offers cloud-based software applications for healthcare markets.
  • Provides solutions for sleep apnea, COPD, and other respiratory conditions.
  • Offers ventilation devices for hospital and home use.
  • Provides diagnostic products and mask systems.
  • Offers cloud-based informatics solutions for patient management.
  • Provides business management software for home medical equipment providers.
  • Offers care management solutions for senior living and skilled nursing facilities.

Business Model

  • Sells medical devices, including CPAP machines and ventilators, to sleep clinics, hospitals, and home healthcare providers.
  • Generates recurring revenue through the sale of masks, accessories, and software subscriptions.
  • Provides cloud-based software solutions for remote patient monitoring and therapy management.
  • Offers business management software and services to healthcare providers.

Industry Context

ResMed operates within the medical instruments and supplies industry, which is experiencing growth driven by an aging population, rising prevalence of chronic diseases, and increasing demand for home healthcare solutions. The market for sleep apnea devices and solutions is particularly robust, fueled by growing awareness and diagnosis rates. ResMed competes with established players like Becton, Dickinson and Company (BDX) and General Electric HealthCare (GEHC), as well as smaller, specialized companies. The industry is characterized by technological innovation, regulatory scrutiny, and evolving reimbursement models.

Key Customers

  • Sleep clinics and hospitals
  • Home healthcare dealers
  • Patients with sleep apnea and other respiratory disorders
  • Senior living and skilled nursing facilities
  • Home health and hospice agencies
AI Confidence: 73% Updated: Feb 9, 2026

Financials

Chart & Info

ResMed Inc. (RMD) stock price: $228.22 (-1.42, -0.62%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RMD.

Price Targets

Consensus target: $287.40

MoonshotScore

52/100

What does this score mean?

The MoonshotScore rates RMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What Investors Ask About ResMed Inc. (RMD)

What does ResMed Inc. do?

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the healthcare market. The company primarily focuses on addressing respiratory disorders, including sleep apnea, COPD, and other chronic conditions. ResMed offers a comprehensive range of products, including CPAP machines, ventilators, diagnostic equipment, and masks, along with cloud-based platforms like AirView and myAir that enable remote patient monitoring and therapy management. The company serves a diverse customer base, including sleep clinics, hospitals, home healthcare providers, and patients in approximately 140 countries.

Is RMD stock worth researching?

RMD stock presents a potentially attractive investment opportunity, underpinned by the company's strong market position, recurring revenue model, and growth catalysts. With a profit margin of 27.5% and a dividend yield of 0.83%, ResMed demonstrates financial strength and shareholder value. The increasing prevalence of sleep apnea and the growing adoption of digital health solutions are expected to drive future growth. However, investors may want to evaluate potential risks, such as changes in reimbursement policies and competition. A balanced analysis of ResMed's valuation, growth potential, and risk factors is crucial before making an investment decision.

What are the main risks for RMD?

ResMed faces several key risks that could impact its financial performance and market valuation. Changes in reimbursement policies or healthcare regulations could significantly affect revenue, particularly for its core sleep apnea devices. Technological advancements by competitors could erode market share if ResMed fails to innovate and adapt. Economic downturns or healthcare spending cuts could reduce demand for its products. Product liability claims or intellectual property disputes could damage its reputation and financial standing. Additionally, currency fluctuations and international risks pose ongoing challenges to its profitability.

What are the key factors to evaluate for RMD?

ResMed Inc. (RMD) currently holds an AI score of 52/100, indicating moderate score. The stock trades at a P/E of 22.3x, near the S&P 500 average (~20-25x). Analysts target $287.40 (+26% from $228.22). Key strength: Market leader in sleep apnea devices and solutions.. Primary risk to monitor: Potential: Changes in reimbursement policies or healthcare regulations could impact revenue.. This is not financial advice.

How frequently does RMD data refresh on this page?

RMD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven RMD's recent stock price performance?

Recent price movement in ResMed Inc. (RMD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $287.40 implies 26% upside from here. Notable catalyst: Market leader in sleep apnea devices and solutions.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider RMD overvalued or undervalued right now?

Determining whether ResMed Inc. (RMD) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 22.3. Analysts target $287.40 (+26% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying RMD?

Before investing in ResMed Inc. (RMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Stock data pending update.
  • This analysis is based on publicly available information and should not be considered financial advice.
Data Sources

Popular Stocks